Acute Lymphoblastic Leukaemia
Published in June 1994
Book
Hardback
224 pages
978-0-7020-1825-1 (ISBN)
Description
A guide to the diagnosis and detection of acute lymphoblastic leukaemia, detailing genetic changes and associated morphological and cytochemical alterations. This work also considers the use of various therapies such as bone marrow transplantation, IL2 and gene therapy, and CNS directed therapy.
A guide to the diagnosis and detection of acute lymphoblastic leukaemia, detailing genetic changes and associated morphological and cytochemical alterations. This work also considers the use of various therapies such as bone marrow transplantation, IL2 and gene therapy, and CNS directed therapy.
A guide to the diagnosis and detection of acute lymphoblastic leukaemia, detailing genetic changes and associated morphological and cytochemical alterations. This work also considers the use of various therapies such as bone marrow transplantation, IL2 and gene therapy, and CNS directed therapy.
More details
Series
Edition
New edition
Language
English
Place of publication
London
United Kingdom
Publishing group
Elsevier Health Sciences
Target group
Professional and scholarly
Edition type
New edition
Dimensions
Height: 230 mm
Weight
1000 gr
ISBN-13
978-0-7020-1825-1 (9780702018251)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Content
Genetic changes - relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia; immunophenotypic classification of acute lymphoblastic leukaemia; morphology and cytochemistry of acute lymphoblastic leukaemia; advances in the therapy for childhood non-B lymphoblastic leukaemia; therapy of B-acute lymphoblastic leukaemia in childhood - the BFM experience; therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma - experience with the LMB protocols of the SFOP (French Pediatric Oncology Society) in children and adults; bone marrow transplantation for acute lymphoblastic leukaemia; autologous bone marrow transplantation in acute lymphoblastic leukaemia; IL2 and gene therapy in the management of acute lymphoblastic leukaemia; central nervous system directed therapy in acute lymphoblastic leukaemia; long-term sequelae of therapy for childhood acute lymphoblastic leukaemia.